lenalidomide has been researched along with Fatigue in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (13.04) | 29.6817 |
2010's | 19 (82.61) | 24.3611 |
2020's | 1 (4.35) | 2.80 |
Authors | Studies |
---|---|
Atherton, PJ; Bartlett, NL; Blum, KA; Dueck, AC; Flowers, CR; Habermann, TM; Jung, SH; Leonard, JP; Novotny, PJ; Pitcher, BN; Tan, A; Thanarajasingam, G; Witzig, TE | 1 |
Almeida, A; Beach, CL; Castaneda, C; Fenaux, P; Garcia-Manero, G; Goldberg, SL; Gröpper, S; Jonasova, A; Santini, V; Vey, N; Zhong, J | 1 |
Gilbert, L; Ordway, S; Wanko, S | 1 |
Alsina, M; Bensinger, WI; Kunkel, LA; Lee, S; Martin, TG; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M; Wong, AF | 1 |
Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A | 1 |
Berardi Vilei, S; Berthod, G; Caspar, C; Eckhardt, K; Fischer, N; Hitz, F; Mey, U; Pabst, T; Zucca, E | 1 |
Alsina, M; Bensinger, W; Huang, M; Kavalerchik, E; Martin, T; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M | 1 |
Eom, HS; Jo, DY; Jun, HJ; Kim, JS; Kim, K; Kim, KH; Kim, SH; Kim, SJ; Kim, YS; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Min, CK; Moon, JH; Mun, YC; Park, SK; Ryoo, HM; Suh, C; Voelter, V; Yoon, SS | 1 |
Aurran-Schleinitz, T; Blaise, D; Bouabdallah, R; Broussais-Guillaumot, F; Chetaille, B; Coso, D; Esterni, B; Ivanov, V; Olive, D; Schiano, JM; Stoppa, AM | 1 |
Anderson, KC; Bianchi, G; Richardson, PG | 1 |
Bartlett, NL; Blum, KA; Cheson, BD; Johnson, J; Jung, SH; LaCasce, A; Morrison, VA; Pitcher, BN | 1 |
Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Terpos, E | 1 |
Liljefors, M; Rossmann, E; Ullenhag, GJ | 1 |
Buckstein, R; Rezmovitz, J; Wells, RA | 1 |
Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kalapanida, D; Kanellias, N; Kastritis, E; Migkou, M; Roussou, M; Terpos, E; Zagouri, F | 1 |
Coelho, I; Esteves, GV; Esteves, S; Freitas, J; Geraldes, C; Gomes, F; João, C; Lúcio, P; Neves, M | 1 |
Amato, RJ; Hernandez-McClain, J; Khan, M; Saxena, S | 1 |
Cole, C; Ervin-Haynes, A; Justice, G; Kaplan, H; Moore, T; Pietronigro, D; Reeder, C; Takeshita, K; Voralia, M; Vose, JM; Wiernik, PH; Witzig, TE; Zeldis, JB | 1 |
Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W | 1 |
Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, P; Hayman, S; Keith Stewart, A; Khan, ML; Kumar, SK; Lacy, MQ; Laumann, KM; Leif Bergsagel, P; Lust, J; Mikhael, JR; Reece, DE; Reeder, CB; Russell, S; Vincent Rajkumar, S; Zeldenhurst, S | 1 |
Locke, FL; Morgan, GJ | 1 |
Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B | 1 |
Bernstein, ZP; Byrne, C; Chanan-Khan, A; Chrystal, C; Czuczman, MS; Goodrich, DW; Hernandez-Ilizaliturri, F; Lawrence, D; Miller, KC; Mohr, A; Musial, L; Padmanabhan, S; Porter, CW; Spaner, D; Starostik, P; Takeshita, K; Wallace, P | 1 |
1 review(s) available for lenalidomide and Fatigue
Article | Year |
---|---|
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid | 2012 |
13 trial(s) available for lenalidomide and Fatigue
Article | Year |
---|---|
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Drug Tolerance; Fatigue; Hematologic Neoplasms; Humans; Infusions, Intravenous; Lenalidomide; Lymphoma, Follicular; Neutropenia; Rituximab; Thrombosis | 2020 |
Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Diarrhea; Exanthema; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Risk Factors; Spasm | 2018 |
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Thalidomide; Treatment Outcome | 2013 |
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptions; Drug Resistance, Neoplasm; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Lenalidomide; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Pain; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; Salvage Therapy; Sorafenib; Thalidomide; Treatment Outcome | 2013 |
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Fatigue; Female; Heart Diseases; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Nitrogen Mustard Compounds; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2013 |
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Remission Induction; Thalidomide; Treatment Outcome | 2013 |
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Lymphopenia; Male; Middle Aged; Nausea; Nervous System Diseases; Recurrence; Remission Induction; Thalidomide; Treatment Outcome | 2015 |
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Injections, Intravenous; Lenalidomide; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreas; Pancreatic Neoplasms; Thalidomide | 2015 |
Lenalidomide therapy for metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Fatigue; Female; Hematologic Diseases; Humans; Kidney Neoplasms; Lenalidomide; Male; Middle Aged; Survival Rate; Thalidomide | 2008 |
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Constipation; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Recurrence; Thalidomide; Time Factors; Treatment Outcome | 2009 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Fatigue; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Pain; Pyrazines; Remission Induction; Sensation Disorders; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid; Male; Middle Aged; Mutation; Nausea; Nuclear Proteins; Nucleophosmin; Prognosis; Remission Induction; Thalidomide; Treatment Outcome; Vomiting | 2013 |
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Thalidomide; Thrombocytopenia | 2006 |
9 other study(ies) available for lenalidomide and Fatigue
Article | Year |
---|---|
POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation.
Topics: Adult; Combined Modality Therapy; Cyclophosphamide; Diagnosis, Differential; Drug Therapy, Combination; Dyspnea; Fatigue; Female; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Polyneuropathies; Prednisone; Thalidomide | 2018 |
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Korea; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Retrospective Studies; Rituximab; Thalidomide; Thrombocytopenia; Treatment Outcome | 2014 |
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulin G; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Referral and Consultation; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Zoledronic Acid | 2014 |
Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach?
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Fatigue; Humans; Hypertension, Renal; Immunoglobulin Light Chains; Kidney; Kidney Failure, Chronic; Lenalidomide; Male; Myalgia; Paraproteinemias; Proteinuria; Remission Induction; Thalidomide | 2014 |
Myelodysplastic syndrome.
Topics: Aged; Anemia, Macrocytic; Bone Marrow; Erythropoietin; Fatigue; Humans; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide | 2016 |
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
Topics: Aged; Aged, 80 and over; Cohort Studies; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Renal Insufficiency; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2016 |
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2012 |